These medications are generally considered a long term, potentially lifelong treatment, as Yet, 32% of people who begin taking GLP-1 weight loss medications stop within a year due to several reasons, including the high cost and severity of side effects
The impact has been vast and further preclinical studies are still necessary to explore and understand the potential of the drugs that have already revolutionised the lives of millions of people with obesity and type 2 diabetes
GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy), dulaglutide (Trulicity), liraglutide (Victoza, Saxenda), and tirzepatide (Mounjaro, Zepbound) are FDA-approved for type 2 diabetes and obesity management
Research also suggests that by facilitating weight loss, GLP-1 medication can indirectly reduce the burden on your other systemshelping to improve symptoms of PCOS, knee osteoporosis, sleep Apnea and even substance use disorders
Your body is changing quickly, and that can feel unsettling